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Abstract
Haematopoietic stem cell transplantation (HSCT) following intensive immune suppression has been used in
>2000 patients with severe autoimmune diseases for 18 years, including 300 with SSc. The concept is to
profoundly reduce the bulk of auto-aggressive immune competent cells and then rescue the patient’s
ablated haematopoiesis via an autologous HSCT. An early analysis of uncontrolled phase I/II data suggested
that approximately one-third of these achieved a substantial improvement, with a relapse rate of 25% and a
treatment-related mortality ranging from 6% to 23% across different studies. These early results led to three
prospective randomized controlled trials, two of which are completed, confirming that HSCT shows clear
advantages over conventional immunosuppression, but with significant toxicity. In some patients, sustained
complete normalization of skin changes, reversal of positive autoantibody status and withdrawal of immuno-
suppressive medication were observed. These results attest to the profound effects of HSCT.
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Rheumatolozgy key messages
. Autologous stem cell transplantation is an effective treatment in selected patients with early dcSSc.
. SSc patients are at risk of serious toxicities including treatment-related death due to major organ involvement
(notably heart, lungs, kidneys).
. Autologous stem cell transplantation in SSc should be performed by expert multidisciplinary teams in specialized
transplant units.
Introduction
For decades, autologous haematopoietic stem cell trans-
plantation (HSCT) has been used to re-establish normal
haematopoiesis after major cytoreductive therapy for
malignant disorders. This allows the administration of
high-dose chemo- and/or radiotherapy since the HSCT
reverses the otherwise severe aplasia that inevitably
follows such treatment. Since the mid-1990s, following
the publications of the successful outcome of the first
transplanted SSc patients and spearheaded by the
Autoimmune Diseases Working Party of the European
Group for Blood and Marrow Transplantation, the
EULAR and the International Stem Cell Project for
Autoimmune Disease, the same approach has been
used to treat selected patients with severe autoimmune
disease (AD) [13].
From the outset it was recommended that only pa-
tients with a severe life- or organ-threatening AD should
be considered for such a potentially toxic therapy. In
addition, it was considered important that patients
with end-stage or permanently severely damaged
organs should not be transplanted, as the therapy was
essentially anti-inflammatory and immunosuppressive
rather than tissue regenerative. In SSc, reversal of fibro-
sis or vascular pathology was not expected. As the pro-
gramme progressed, some gratifyingly positive results
regarding regression of fibrosis and de-remodelling of
the vasculature were observed in transplanted SSc pa-
tients, reminding us that the complexity of the cellular
players in the three-dimensional niche of AD pathology
is far from fully understood.
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HSCT for SSc
At the inception of the programme, biologics had not yet
become available and every AD subgroup had many
cases severe enough to be considered for HSCT, notably
those who had failed conventional therapy and had active
inflammatory disease, which if slowed or arrested would
still result in a significant quality of life. An early analysis of
the phase I/ II data showed that significant numbers of
patients in all AD subgroups had benefited from autolo-
gous HSCT, with the highest sustained responses seen in
SSc [3]. Less toxic and effective therapeutic alternatives
have evolved for many ADs, reducing the need for HSCT
in diseases such as RA and JIA. In contrast, SSc remains
a difficult-to-treat condition despite the therapeutic use of
ACE inhibitors for scleroderma renal crisis, endothelin-1
receptor antagonists for pulmonary arterial hypertension
(PAH) and immunosuppressants such as MMF [4, 5]. In
addition, predictors of poor outcome such as PAH,
reduced diffusion capacity of the lung for carbon monox-
ide (DLCO) and functional status are becoming better
defined [6]. However, HSCT in SSc was associated with
higher toxicity, not only related to known risk factors for
HSCT such as the age of the patient, time from diagnosis
to transplant, co-morbidity and regimen intensity, but
also SSc-associated co-morbidities such as severe
PAH, reduced left ventricular ejection fraction (LVEF) or
ventricular tachyarrhythmias [7].
Which transplant regimen is best?
In the absence of adequate data, many theoretical argu-
ments were put forward to support allogeneic HSCT as
the best option for inducing remission. The main reason
proposed was the need to replace an auto-aggressive
corrupted immune system with a healthy one. While this
made some sense, there were facts and findings
that challenged this. First, the concordance rate of SSc
(and most other ADs) in monozygotic twins is relatively
low, indicating that stem cells and immune cells from gen-
etically predisposed individuals are not necessarily pro-
grammed to become auto-aggressive [8]. In addition,
there were case reports of RA patients receiving allogen-
eic HSCT for aplastic anaemia in whom later relapse was
associated with full chimerism of the previously healthy
immune competent cells [9]. More importantly, allogeneic
HSCT is associated with graft-vs-host disease, a compli-
cation not present in the autologous situation. This unin-
tended consequence was indeed observed in one of two
SSc patients treated with allogeneic HSCT, with the other
patient reportedly having improved significantly [10]. In an
analysis of 38 allogeneic transplants in 35 patients with
various haematological/non-haematological ADs (none
with SSc), treatment-related mortality (TRM) was 22.1%
[11]. This high percentage must of course be interpreted in
the context of the severity of the disease in these patients,
which in the absence of data from a control group is a
daunting task.
The case for autologous HSCT was sealed, however,
when studies in animal models of AD demonstrated that
not only allogeneic but also autologous HSCT could
induce sustained remission [12]. Of note, none of these
included animal models of SSc. Further discussions
centred around the issue of the degree of intensity of
the conditioning regimens required; in other words, to
what extend should one try to eliminate the host’s auto-
reactive immune competent cells as opposed to inducing
regulation?
At each step of autologous HSCT it is possible to
employ varying intensities of treatment, including the
complete omission of graft manipulation or purging. This
does not exclude removal of unwanted immune compe-
tent lymphocytes since, on reinfusion after conditioning,
the anti-thymocyte globulin (ATG) lyses many of these
in vivo. The result is a less prolonged period of immuno-
suppression than that seen by extensive ex vivo purging.
In the absence of data from comparative trials, a limited
number of protocols were pursued, with a suggestion later
that the intermediate intensity regimen offered the best
compromise between efficacy and toxicity [13]. A typical
intermediate intensity regimen is mobilization with CYC
2 1 g/m2 body area and G-CSF, ex vivo CD34 selection
of the graft and conditioning with CYC 200 mg/kg
body weight combined with rabbit ATG 7.5 mg/kg body
weight, a regimen used in the Autologous Stem Cell
Transplantation International Scleroderma (ASTIS) trial
(see below). The available data do not allow conclusions
as to which autologous transplant regimen is best since
head-to-head studies have not been done, but the re-
cently updated guidelines reaffirm the preference for
autologous as opposed to allogeneic HSCT [14].
Treatment-related mortality of HSCT
in SSc—results from pilot studies
Whatever the choice of regimen intensity, it is clear that
even autologous HSCT protocols carry a finite TRM,
which in all but the smallest studies in SSc patients has
ranged from 6% to 17% with non-irradiation-based treat-
ment protocols (Table 1) [15]. In a North American pilot
study, 8 of 34 SSc patients (23%) died from treatment-
related complications following mobilization with G-CSF,
subsequent CD34 selection of the graft and conditioning
with high-dose CYC, ATG and fractionated total body
irradiation (TBI) [16]. The US investigator group amended
their protocol to include lung and kidney shielding to mini-
mize the risk of organ toxicity from TBI and continued to
refine their protocol as a basis for the Scleroderma:
Cyclophosphamide or Transplantation (SCOT) trial (see
below). In comparison with transplant results in other
ADs, TRM in SSc patients has been relatively high, and
this has been ascribed to the severity of disease and the
presence of major organ dysfunction in transplanted SSc
patients [21]. In general, TRM in HSCT settings is related
to the transplant regimen used (e.g. cardiotoxocity from
high-dose CYC), patient selection and centre effect. It has
proved very difficult to extract meaningful comparative
information on this from the different pilot studies and
registry analyses published to date. Interpretation is
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hampered by the use of different definitions for TRM, the
lack of autopsy results and the absence of independent
data monitoring committees for adjudication of causes
of death.
Outcome measurement in SSc
Currently no internationally agreed criteria exist for remis-
sion in SSc, although international collaboration is on-
going regarding outcome measurement in SSc clinical
trials [24]. It would seem reasonable to assume that if
the clinical activity score is minimal and vital organ func-
tion stabilizes in a patient not receiving significant
immunosuppressive agents, then for all intents and pur-
poses a remission can be assumed [25]. It is important to
note that the diffuse cutaneous form of SSc often shows a
spontaneous time-dependent improvement in skin thick-
ness, measured by the modified Rodnan skin score
(mRSS). This may occur in approximately two-thirds of
patients and is associated with improved survival [26].
This should be taken into account in any clinical trial
using the mRSS as an outcome measure. In addition, im-
provement of skin thickening on the chest wall will be re-
flected by an improvement in the forced vital capacity, but
not necessarily improved interstitial lung disease. It was
observed early in the AD transplant programme that a
number of patients relapse after an initial improvement
following HSCT. In contrast to malignancies, where the
term relapse has been defined, no accepted operational
definitions are available for rheumatological diseases such
as SSc. The difficulties with defining such outcomes are
not unique to SSc, as illustrated by the lack of consensus
on the meaning of flare in RA. In contrast, one can envis-
age that the stark improvements of disease activity
in transplanted SSc patients may provide a unique oppor-
tunity to test or validate new constructs such as
remission.
Outcomes in SSc following autologous
HSCT
Early in the international AD transplant programme, case
reports and small series were published suggesting sig-
nificant improvement in both survival and morbidity
following autologous HSCT. The first published case of a
patient receiving an HSCT as specific treatment for an AD
was a case of SSc with PAH (mean pulmonary artery pres-
sure 50 mmHg) in whom a sustained improvement in both
mean pulmonary artery pressure (37 mmHg) and general
clinical state was observed [1]. From early registry data in
41 SSc patients, approximately one-third of SSc patients
achieved a sustained remission, with a TRM of 17% [7].
This later fell to 8.7% through further experience and
increased patient numbers [27]. Similar positive outcomes
were observed also in the USA [16]. As mentioned above,
pulmonary and renal toxicity related to TBI was observed
in the first group of patients, which was later mostly abro-
gated by selective lung and kidney shielding.
In general, all involved groups experienced a learning
curve regarding toxicity. Examples include the following:
rapid fluid and electrolyte shifts and glucocorticoid infu-
sions are risk factors for scleroderma renal crisis and tight
control of fluid status and prophylactic angiotensin-
converting enzyme (ACE) inhibition has been used to miti-
gate this in the ASTIS trial; comprehensive pre-transplant
cardiac screening and, when indicated (ventricular
tachyarrhythmias), implantation of a defibrillating pace-
maker [28]; and the use of adequate glucocorticoid ther-
apy during the ATG infusion to reduce cytokine storm
events.
In most studies done to date, HSCT consistently led to
unprecedented and rapid improvements in mRSS and
functional capacity (HAQ Disability Index), and stabiliza-
tion of organ function [LVEF, vital capacity (VC), DLCO,
creatinine clearance]. Furthermore, encouraging data
emerged regarding changes in collagen deposition in
involved skin and improved microcirculation in skin and
nail folds [2932]. The mechanism for such profound and
mostly sustained changes remains elusive, since none of
the individual agents used in the mobilization and
conditioning components of the HSCT regimen are
active directly on collagen-producing myofibroblasts,
angiogenesis-competent endothelial cells and pericytes.
It is conceivable, however, that the anti-fibrotic effects
of HSCT result from disruption of the crosstalk between
immune cells and stromal cells (reviewed in Hu¨gle and van
Laar [33]).
The encouraging data from registry studies and phase
I/II trials were considered sufficient to justify confirmatory
randomized controlled trials (RCTs). It was important to
establish whether HSCT impacted on clinically meaningful
endpoints such as event-free survival and organ damage
rather than just changes in skin score and organ function
when compared head-to-head with standard chemother-
apy. In addition, such trials also provide material and data
for mechanistic studies to try to understand how the re-
missions observed were achieved in order to fine tune
future studies to maximize benefit and reduce risk.
Prospective randomized trials
To date, three prospective RCTs have been completed
with HSCT in SSc (Table 2). Due to the profound clinical
effects of HSCT, blinding of clinicians, patients and asses-
sors for outcome measures is not possible. This should
be taken into account when interpreting the effects on
TABLE 1 HSCT-related mortality in SSc studies and trials
with 10 or more transplanted patients
Reference Treatment-related death, n/N (%)
Nash et al. [16] 8/34 (23.6)
Binks et al. [7] 7/41 (17.1)
Henes et al. [17] 3/26 (11.6)
van Laar et al. [18] 8/75 (10.7)
Farge et al. [19] 1/11 (9.1)
Burt et al. [20] 5/90 (5.6)
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subjective measures such as skin thickening and patient-
reported outcomes. Nevertheless, the results from the two
completed phase III RCTs to date are entirely consistent
with the published data from pilot studies, registry ana-
lyses and a small phase II RCT.
The ASSIST trial was the first published randomized trial
to demonstrate superior efficacy of HSCT vs 6 monthly
pulses of CYC (1 g/m2) on skin thickness, lung function
and quality of life [34]. This North American single-centre
phase II trial involved only 19 patients, 10 of whom were
randomized to HSCT and 9 to pulse CYC. Crossing over
was allowed, and eight of nine control patients received
HSCT because of an unsatisfactory response to pulse
CYC. Baseline characteristics of the two groups differed
slightly due to the small sample size, but the authors men-
tioned that this had not affected the outcome of the trial.
Also, the number and dosing of CYC in the control group
were lower than used in clinical practice, which may have
contributed to the observed substantial differential effect
of the two interventions. Importantly, no patient died
during the study and serious toxicities were uncommon.
While these favourable toxicity data could be testament to
the experience of the clinical team, it cannot be ruled out
that these are chance findings related to the small sample
size and the relatively short observation period (up to
2 years after HSCT). Furthermore, the trial was stopped
early for benefit, an important caveat since such trials tend
to overestimate clinical efficacy [22].
The first completed and published phase III randomized
trial in the field was the ASTIS trial [18]. This international
clinical trial involved 156 patients with poor-prognosis
early dcSSc enrolled via 29 centres (28 in Europe and
1 in Canada) from 2001 to 2009. Patients were randomized
to either HSCT or 12 monthly pulses of CYC (750 mg/m2).
The trial, with a median follow-up of 5.8 years, showed
that HSCT significantly prolonged event-free survival (the
primary endpoint), defined as overall survival minus the
occurrence of major organ failure of heart, lungs or kid-
neys according to pre-specified criteria, and overall sur-
vival (Fig. 1) [31]. Fifty-three events occurred: 22 in the
HSCT group (19 deaths and 3 irreversible organ failures)
and 31 in the control group (23 deaths and 8 irreversible
organ failures, 7 of whom died later). Secondary endpoints
defined as the change in the first 2 years of mRSS, HAQ,
EuroQoL, or the 36-item Short Form Health Survey were
also significantly better in the HSCT group. No significant
changes were seen for LVEF or DLCO, but a modest but
statistically significant decrease in creatinine clearance
and an increase in FVC/VC was seen in the HSCT
group. In terms of toxicity, more grade 3 and 4 serious
adverse events were documented in the HSCT group,
mainly related to febrile neutropenia. Also, more viral in-
fections occurred after HSCT, including two cases of
EBV-related post-transplant lymphoproliferative disease,
one of which was successfully treated with rituximab
while the other had a fatal outcome. TRM in the HSCT
TABLE 2 Main eligibility criteria of HSCT randomized controlled trials in SSc
Trial ASTIS ASSIST SCOT
Main inclusion criteria 1665 years of age <60 years of age <65 years of age
Diffuse SSc: 42 years since
development of first sign of skin
thickening, mRSS 520,
involvement of trunk, ESR
>25 mm/h and/or Hb <11 g/dl;
or44 years since development
of first sign of skin thickening,
mRSS 515, major organ
involvementa
Diffuse SSc: cutaneous
involvement proximal to
the elbow or knee,
mRSS >14b, internal
organ involvementc,
disease duration
44 years
Diffuse SSc: mRSS 516,
sSignificant visceral organ
involvementd, disease
duration 44 years
Main exclusion criteria Mean PAP >50 mmHg, DLCO
<40%, respiratory failuree,
LVEF by MUGA or cardiac echo
<45%, creatinine clearance
<40 ml/min, prior treatment
with TLI, TBI or alkylating
agents including CYC (total
cumulative i.v. dose of >5 g, or
>3 months oral up to 2 mg/kg
body weight)
Mean PAP >25 mmHg or
PASP >40 mmHg, TLC
<45% (predicted), LVEF
<40%, serum creatinine
>177 mmol/l, prior
treatment with >6 i.v.
injection of CYC
DLCO <45% or using supple-
mental oxygen at rest; severe
heart, liver or kidney impair-
ment; active GAVE; prior
treatment with I.V. CYC for >6
months or a total cumulative
i.v. dose >3 g/m2; oral CYC
for >4 months, regardless of
dose; or a combination of oral
and i.v. CYC for >6 months,
independent of dose
aMajor organ involvement defined as involvement of lung, kidney or heart. bIn cases of restricted skin involvement
(mRSS <14), patients were eligible only if they had coexistent pulmonary involvement. cInternal organ involvement was
defined as involvement of lung, heart or gastrointestinal tract. dSignificant visceral organ involvement was defined as involve-
ment of lung, heart or kidney. eRespiratory failure was defined by resting arterial oxygen tension (PaO2) <8 kPa (<60 mmHg)
and/or resting arterial carbon dioxide tension (PaCO2) >6.7 kPa (>50 mmHg) without oxygen supply. DLCO: diffusion capacity
of the lung for carbon monoxide; GAVE: gastric antral vascular ectasia; Hb: haemoglobin; LVEF: left ventricular ejection
fraction; mRSS: modified Rodnan skin score; MUGA: multiple gated acquisition scan; PAP: pulmonary artery pressure;
PASP: pulmonary artery systolic pressure; TBI: total body irradiation; TLC: total lung capacity; TLI: total lymphoid irradiation.
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group was 10.1%, which was mainly accounted for by
cardiopulmonary insufficiency during conditioning, pos-
sibly from the administration of ATG and the resulting
cytokine release syndrome. Every case was thoroughly
reviewed by an independent data monitoring committee,
who adjudicated each cause of death as being either
treatment related or due to disease progression or an un-
related cause. No patient in the control group died from
treatment-related complications, and most fatalities were
due to disease progression. A post hoc analysis revealed
FIG. 1 Event-free survival and overall survival over a 10 year follow-up period
A
B
Time-varying hazard ratios, P = .04
FU, y: HR (95%CI), P Value_________________________
 ¼ : 2.01 (0.74 - 5.49), .17
 ½ : 1.35 (0.62 - 2.96), .45
  1 : 0.52 (0.28 - 0.96), .04
  2 : 0.35 (0.16 - 0.74), .006
  3 - 10 : 0.34 (0.16 - 0.74), .006
0
20
40
60
80
100
E
ve
nt
-fr
ee
 s
ur
vi
va
l (
%
)
79 66 65 65 64 53 41 29 21 13 10Transplant
77 69 63 60 57 40 33 23 17 11 6Control
Number at risk
0 1 2 3 4 5 6 7 8 9 10
Years
Control Transplant
Time-varying hazard ratios, P = .03
FU, y: HR (95%CI), P Value_________________________
 ¼ : 2.40 (0.75 - 7.67), .14
 ½ : 1.50 (0.61 - 3.68), .38
  1 : 0.48 (0.25 - 0.91), .02
  2 : 0.29 (0.13 - 0.65), .002
  3 - 10 : 0.29 (0.13 - 0.64), .002
0
20
40
60
80
100
O
ve
ra
ll 
su
rv
iv
al
 (%
)
79 68 67 67 66 55 43 32 23 14 11Transplant
77 70 64 60 57 40 34 25 18 12 6Control
Number at risk
0 1 2 3 4 5 6 7 8 9 10
Years
Control Transplant
(A) KaplanMeier curves for event-free survival. (B) KaplanMeier curves for overall survival. Hazard ratios and 95% CIs
were calculated by Cox regression. Hazard ratios were time varying. Figure adapted from van Laar JM et al. [18].
Published with permission from the American Medical Association, copyright ! 2014 American Medical Association.
All rights reserved.
2130 www.rheumatology.oxfordjournals.org
Jacob M. van Laar et al.
that seven of eight cases of TRM in the HSCT group
occurred in ever smokers, while non-smokers enjoyed
the greatest survival benefit after HSCT. The TRM in the
ASTIS trial is in the range of TRMs reported in the pilot
studies and should be interpreted in the context of dis-
ease severity. It is conceivable that HSCT in less
advanced disease will prove safer, but this remains to
be demonstrated. The problem of cytokine release syn-
drome during HSCT is well recognized and new treatment
options are being tested [35].
Whatever one reads into the aforementioned results, it
must be remembered that the ASTIS trial was designed as
a proof-of-principle study, which for the first time demon-
strated that intensive immunosuppressive treatment in
early dcSSc fundamentally alters the long-term outcome
of patients with poor-prognosis SSc. Furthermore, its re-
sults suggested that patients can be stratified on the basis
of a simple feature, such as smoking status, into those at
risk of serious toxicity and TRM (ever smokers) and those
with a high probability of enjoying a favourable outcome
(non-smokers). However, these findings from post hoc
analyses need to be confirmed in other trials or large
registry studies before policy decisions can be made
with some confidence. At present, it is unclear how smok-
ing status affects the outcome of HSCT, but the observa-
tion of a link between smoking status and outcome after
HSCT in SSc is consistent with similar results in other
transplant settings [36].
The North American SCOT trial used eligibility criteria
broadly similar to those of the ASTIS trial and an almost
identical control treatment, only differing in the specifics of
the HSCT regimen (with TBI) and the definition of end-
points. Accrual in the SCOT trial has been completed
but the results have not yet been published. The simila-
rities between the ASTIS and SCOT trials will allow com-
parative analyses that may help to identify the optimal
patient profile for HSCT and determine whether details
of transplant regimens matter. The patient populations in
both trials are relatively homogeneous in terms of the
extent of skin thickening, organ involvement and disease
duration, and the intensive screening procedures have re-
vealed that some manifestations previously thought to be
rare, such as gastric antral vascular ectasia, are actually
quite common in this particular subgroup [37].
Long-term follow-up of transplanted SSc patients is es-
sential to identify known late sequelae of HSCT, such as
secondary AD and malignancy [38]. HSCT is an expensive
treatment, and health care providers and patients have a
right to be informed about the pros and cons of HSCT as
opposed to conventional immunosuppression. In this
context, it is worth noting that the literature on the long-
term benefits and adverse effects of conventional
immunosuppressive treatments such as MMF and MTX
in SSc patients is scarce, if existent at all. As yet there
has not been a breakthrough with biologic treatment in
SSc, although some positive results have been recently
reported with B cell depletion [23, 39]. While encouraging,
conclusive evidence of the efficacy of biologics can
only be obtained via prospective RCTs, because of the
heterogeneity of the disease and its unpredictable disease
course.
Conclusion
There is now ample evidence that HSCT can result in
significant improvement of skin thickness and functional
ability in SSc, while the recently completed ASTIS trial
demonstrated that HSCT can also prolong survival in se-
lected patients with dcSSc when compared with i.v. pulse
CYC. Smoking status affected outcome after HSCT in the
ASTIS trial. Further analyses and studies are needed to
determine whether HSCT should be offered as first-line
chemotherapy or as salvage treatment for those not re-
sponding to i.v. pulse CYC. HSCT in SSc is associated
with serious toxicities that may be fatal. Some investiga-
tors advocate the use of intravascular fluid challenge of
the heart to detect subclinical cardiac involvement and
exclude those allegedly at risk of complications from con-
ditioning, including hyperhydration, but this is not stand-
ard practice in most transplant centres [20]. A thorough
cardiac workup is necessary though, in accordance with
published guidelines [40]. The prophylactic use of ACE
inhibitors in HSCT patients, as recommended in the
ASTIS trial, is an area of controversy since a recent
study revealed an association between prior use of ACE
inhibitors and death from scleroderma renal crisis [41].
The number of cases of scleroderma renal crisis in the
ASTIS trial was low, however, thus not substantiating
the concerns raised. Further studies are needed to opti-
mize patient selection so as to reduce toxicity and define
those patients most likely to benefit from the procedure.
This requires identification of poor-prognosis SSc patients
at an early stage before advanced and irreversible organ
involvement has occurred. While major progress has been
made to delineate predictive features of poor outcome on
a patient population level, our ability to do so on an indi-
vidual patient level is still imperfect [42, 43]. Given the low
prevalence of severe SSc and the complexities of HSCT in
these patients, HSCT is probably best performed in spe-
cialist stem cell transplant units with access to multidis-
ciplinary teams that include not only haematologists, but
also rheumatologists with experience in the management
of severe SSc, cardiologists and pulmonologists.
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